According to results from a retrospective study, single-agent enfortumab vedotin demonstrated real-world efficacy among previously treated patients with metastatic urothelial carcinoma.
Long-term data from ZUMA-2 displayed durable responses with brexu-cel in relapsed/refractory mantle cell lymphoma.
Although different adverse pathology definitions predict a higher risk of biochemical recurrence, metastasis, castrate-resistant prostate cancer, and prostate cancer–specific mortality, the absolute …
James J. Harding, MD, reviews the ongoing phase 3 CheckMate 9DW trial, which is investigating nivolumab plus ipilimumab (NIVO + IPI) vs lenvatinib or sorafenib…
Despite the increasing number of women in medicine, gender disparities in leadership and career advancement, particularly in oncology, remain prominent. Addressing issues such as pay…
A stem cell donor changed Laura Tiberi’s life after her leukemia diagnosis. Now she’s sharing hope and inspiration with other transplant recipients.
An abstract is unavailable.
The EMA’s CHMP has recommended the approval of an expanded indication for dostarlimab plus chemotherapy in primary advanced/recurrent endometrial cancer.
Subcutaenous mosunetuzumab plus polatuzumab vedotin demonstrates improved efficacy and response rates compared with rituximab plus polatuzumab vedotin for patients with relapsed/refractory (R/R) LBCL, according to…
Every holiday season, Fox Chase Cancer Center’s Tree of Life Celebration brings together patients, families, donors, researchers, and medical staff to pay tribute to all…
The FDA granted priority review to sunvozertinib for the treatment of advanced NSCLC with EGFR exon 20 mutations, based on promising efficacy and safety data…
